Relmada Therapeutics jumps on NDV-01 12-month Phase 2 data and $160M private placement

Relmada Therapeutics (RLMD) is up 34.8% today. Here is some analysis on what might have caused this price movement.

Analysis: Shares appear to be rising after the company released 12-month interim Phase 2 data for NDV-01 in high-risk non-muscle invasive bladder cancer, highlighting response durability and a favorable safety/tolerability profile. The move may have been amplified by a simultaneous announcement of an oversubscribed $160 million private placement, which investors could be viewing as a vote of confidence and a way to fund the planned registrational program.

Details:

Relmada reported a 76% complete response rate at 12 months in the overall high-risk NMIBC Phase 2 cohort, with a 95% complete response rate “at any time” during follow-up.

In the BCG-unresponsive subgroup, the company disclosed an 80% complete response rate at 12 months and 94% complete response “at any time,” with no Grade 3 or higher treatment-related adverse events and no treatment-related discontinuations.

The company said it expects to pursue IND clearance and initiate the Phase 3 RESCUE registrational program in mid-2026, with an initial Phase 3 readout timeline targeted for year-end 2026.

Relmada also announced an oversubscribed private placement expected to raise about $160.0 million gross, including common shares priced at $4.75 and pre-funded warrants, with an expected closing on or about March 11, 2026.

Sources:

U.S. SEC, GlobeNewswire, Stock Titan

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$RLMD Insider Trading Activity

$RLMD insiders have traded $RLMD stock on the open market 6 times in the past 6 months. Of those trades, 6 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $RLMD stock by insiders over the last 6 months:

MAGED SHENOUDA (Chief Financial Officer) has made 2 purchases buying 511,665 shares for an estimated $1,148,059 and 0 sales.
SERGIO TRAVERSA (Chief Executive Officer) has made 2 purchases buying 300,000 shares for an estimated $712,800 and 0 sales.
CHUCK ENCE (CAO and COO) purchased 136,000 shares for an estimated $299,200
PAUL EDWARD KELLY (Chief Operating Officer) purchased 90,000 shares for an estimated $198,000

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$RLMD Hedge Fund Activity

We have seen 53 institutional investors add shares of $RLMD stock to their portfolio, and 15 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JANUS HENDERSON GROUP PLC added 7,270,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $35,114,100
MARSHALL WACE, LLP added 2,917,609 shares (+1072.4%) to their portfolio in Q4 2025, for an estimated $14,092,051
ORBIMED ADVISORS LLC added 2,610,600 shares (+inf%) to their portfolio in Q4 2025, for an estimated $12,609,198
AMERIPRISE FINANCIAL INC added 1,920,099 shares (+inf%) to their portfolio in Q4 2025, for an estimated $9,274,078
MILLENNIUM MANAGEMENT LLC added 1,673,017 shares (+inf%) to their portfolio in Q4 2025, for an estimated $8,080,672
BRAIDWELL LP added 1,582,257 shares (+inf%) to their portfolio in Q4 2025, for an estimated $7,642,301
IKARIAN CAPITAL, LLC added 1,225,299 shares (+66.5%) to their portfolio in Q4 2025, for an estimated $5,918,194

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$RLMD Analyst Ratings

Wall Street analysts have issued reports on $RLMD in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Leerink Partners issued a "Outperform" rating on 01/23/2026
Jefferies issued a "Buy" rating on 12/22/2025
Mizuho issued a "Outperform" rating on 11/19/2025

To track analyst ratings and price targets for $RLMD, check out Quiver Quantitative's $RLMD forecast page.

$RLMD Price Targets

Multiple analysts have issued price targets for $RLMD recently. We have seen 4 analysts offer price targets for $RLMD in the last 6 months, with a median target of $9.5.

Here are some recent targets:

Christopher Liu from LUCID CAPITAL MARKETS set a target price of $14.0 on 03/02/2026
Andrew Berens from Leerink Partners set a target price of $8.0 on 01/23/2026
Farzin Haque from Jefferies set a target price of $9.0 on 12/22/2025
Uy Ear from Mizuho set a target price of $10.0 on 11/19/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.